Sanofi expands its U.S. manufacturing with a $20 billion investment. The FDA approves Merck's cancer drug for rare adrenal ...

“We want to create a framework for vaccine makers that they can use so they have a predictable FDA where they don’t have to worry how is this going to be received.” The FDA is a massive ...

4 1. FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck & Co. Inc.’s (NYSE:MRK) Welireg (belzutifan) for adult and pediatric patients 12 years and older with locally advanced ...

"Without trials, it is only a matter of time before the FDA approves a vaccine that causes some bad outcome like vaccine-induced narcolepsy. If this happens, you can kiss faith in vaccines goodbye.

But the FDA and the Centers for Disease Control and Prevention (CDC) released a safety notice on May 9 recommending that adults over 60 years old pause use of the vaccine due to fatal complications.

US FDA Approves AbbVie's Drug for a Type of Lung ... Other treatment options for NSCLC include Merck's blockbuster Keytruda and AstraZeneca's Tagrisso, which belong to different classes of drugs.

FDA approved Merck's Welireg as the first oral therapy for advanced pheochromocytoma or paraganglioma (PPGL). In the LITESPARK-015 trial, Welireg showed a 26% ORR and a 20.4-month median duration ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck & Co. Inc.’s (NYSE:MRK) Welireg (belzutifan) for adult and pediatric patients 12 years and older with locally advanced, ...